Mirabegron

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Mirabegron
Mirabegron.svg
Systematic (IUPAC) name
2-(2-Amino-1,3-thiazol-4-yl)-N-[4-(2-{[(2R)-2-hydroxy-2-phenylethyl]amino}ethyl)phenyl]acetamide
Clinical data
Trade names Myrbetriq (US), Betanis (JP), Betmiga (EU, RU)
License data
Pregnancy
category
  • US: C (Risk not ruled out)
Routes of
administration
Oral (tablets)
Legal status
Legal status
  • UK: POM (Prescription only)
  • US: ℞-only
  • ℞ (Prescription only)
Pharmacokinetic data
Bioavailability 29–35%[1]
Protein binding 71%[1]
Metabolism Hepatic via (direct) glucuronidation, amide hydrolysis, and minimal oxidative metabolism in vivo by CYP2D6 and CYP3A4. Some involvement of butylcholinesterase[1]
Biological half-life 50 hours[1]
Excretion Urine (55%), faeces (34%)[1]
Identifiers
CAS Number 223673-61-8
ATC code G04BD12 (WHO)
PubChem CID 9865528
ChemSpider 8041219
Synonyms YM-178
Chemical data
Formula C21H24N4O2S
Molar mass 396.506 g/mol

Mirabegron (trade name Myrbetriq meer-BET-trick in the US and Betmiga in Europe) is a drug for the treatment of overactive bladder.[2] It was developed by Astellas Pharma and was approved in the United States in July 2012.[3]

Mirabegron activates the β3 adrenergic receptor in the detrusor muscle in the bladder, which leads to muscle relaxation and an increase in bladder capacity.[4]

Medical uses[edit]

Its primary use is in the treatment of overactive bladder.[1][5][6]

Mirabegron has also recently been shown to activate brown fat and increase metabolism. In a small study of 15 healthy, lean men, Mirabegron was shown to increase basal heart rate, metabolic rate and blood pressure which are signs of cardiovascular stimulation.[7]

Recently, mirabegron was shown to relax in vitro human and rabbit prostate smooth muscle through activation of β3 adrenoceptor.[8] The same group also showed that mirabegron promotes smooth muscle relaxation by α1 adrenergic receptor blockade.[9]

Adverse effects[edit]

Adverse effects by incidence:[1][5][6]

Very common (>10% incidence) adverse effects include:

Common (1–10% incidence) adverse effects include:

Rare (<1% incidence) adverse effects include:

References[edit]

  1. ^ a b c d e f g "mirabegron (Rx) - Myrbetriq". Medscape Reference. WebMD. Retrieved 17 November 2013. 
  2. ^ Gras, J (2012). "Mirabegron for the treatment of overactive bladder". Drugs of today (Barcelona, Spain : 1998). 48 (1): 25–32. doi:10.1358/dot.2012.48.1.1738056. PMID 22384458. 
  3. ^ Sacco, E; Bientinesi, R; et al. (Apr 2014). "Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence". Expert Opin Drug Discov. 9 (4): 433–48. doi:10.1517/17460441.2014.892923. PMID 24559030. 
  4. ^ "New Drug Approvals 2012 - Pt. XIV - Mirabegron (MyrbetriqTM)". ChEMBL. 5 July 2012. Retrieved 28 September 2012. 
  5. ^ a b "MYRBETRIQ (mirabegron) tablet, film coated, extended release [Astellas Pharma US, Inc.]". DailyMed. Astellas Pharma US, Inc. September 2012. Retrieved 17 November 2013. 
  6. ^ a b "Betmiga 25mg & 50mg prolonged-release tablets". electronic Medicines Compendium. Astellas Pharma Ltd. 22 February 2013. Retrieved 17 November 2013. 
  7. ^ Cypess, Aaron; Weiner, Lauren; Roberts-Toler, Carla; Elía, Elisa; Kessler, Skyler; Kahn, Peter; English, Jeffrey; Chatman, Kelly; Trauger, Sunia; Doria, Alessandro; Kolodny, Gerald (6 January 2015). "Activation of Human Brown Adipose Tissue by a β3-Adrenergic Receptor Agonist". Cell Metabolism. 21 (1): 33–38. doi:10.1016/j.cmet.2014.12.009. PMID 25565203. Retrieved 26 January 2015. 
  8. ^ Calmasini, F. B., T. Z. Candido, E. C. Alexandre, C. A. D'Ancona, D. Silva, M. A. de Oliveira, G. De Nucci, E. Antunes and F. Z. Monica (2015). "The beta-3 adrenoceptor agonist, mirabegron relaxes isolated prostate from human and rabbit: new therapeutic indication?" Prostate 75(4): 440-447.
  9. ^ Alexandre, E C; Kiguti, L R; Calmasini, F B; Silva, F H; da Silva, K P; Ferreira, R; Ribeiro, C A; Mónica, F Z; Pupo, A S (2015-10-01). "Mirabegron relaxes urethral smooth muscle by a dual mechanism involving β3-adrenoceptor activation and α1-adrenoceptor blockade". British Journal of Pharmacology: n/a–n/a. doi:10.1111/bph.13367. ISSN 1476-5381. 

External links[edit]